晕痣的研究进展

doi:10.35541/cjd.20230318

Abstract

Li Rui, Li Hongyang, Zhou Jia, Zhang Wei, Zeng Xuesi. Research progress in halo nevi[J]. Chinese Journal of Dermatology,2023,e20230318. doi:10.35541/cjd.20230318

References ［35］

［1］	De Giorgi V, Colombo J, Salvati L, et al. Eruptive halo nevi: a new COVID⁃19 vaccine⁃related cutaneous adverse event or a paraneoplastic phenomenon?［J］. Dermatol Ther, 2022,35（9）:e15722. doi: 10.1111/dth.15722.
［2］	Jia WX, Zhang YY, Li CR. Four⁃color halo congenital nevus［J］. J Cosmet Dermatol, 2021,20（11）:3712⁃3713. doi: 10.1111/jocd.14056.
［3］	Babu A, Bhat MR, Dandeli S, et al. Throwing light onto the core of a halo nevus: a new finding［J］. Indian J Dermatol, 2016,61（2）:238. doi: 10.4103/0019⁃5154.177801.
［4］	Hassab⁃El⁃Naby H, Rageh MA. Agminated halo nevus: a novel presentation［J］. Am J Dermatopathol, 2023,45（6）:388⁃390. doi: 10.1097/DAD.0000000000002417.
［5］	Rongioletti F, Cecchi F, Rebora A. Halo phenomenon in melanocytic nevi（Sutton′s nevi）. Does the diameter matter?［J］. J Eur Acad Dermatol Venereol, 2011,25（10）:1231⁃1232. doi: 10.1111/j.1468⁃3083.2010.03790.x.
［6］	Haynes D, Strunck JL, Said J, et al. Association between halo nevi and melanoma in adults: a multicenter retrospective case series［J］. J Am Acad Dermatol, 2021,84（4）:1164⁃1166. doi: 10.1016/j.jaad.2020.08.056.
［7］	Yamazaki E, Irimada M, Sasaki R, et al. Multiple halo nevi associated with Turner syndrome［J］. J Dermatol, 2021,48（1）:e11⁃e12. doi: 10.1111/1346⁃8138.15643.
［8］	黄新绿, 杜娟, 徐前喜, 等. 晕痣的流行病学调查、临床特征及皮肤镜表现［J］. 中国皮肤性病学杂志, 2021,35（12）:1371⁃1376.doi:10.13735/j.cjdv.1001⁃7089.202106084
［9］	Pogorzelska⁃Antkowiak A, Corneli P, Agozzino M. In vivo reflectance confocal microscopy of halo nevi［J］. Skin Res Technol, 2021,27（5）:841⁃845. doi: 10.1111/srt.13029.
［10］	Pan C, Shang J, Jiang H, et al. Transcriptome analysis reveals the molecular immunological characteristics of lesions in patients with halo nevi when compared to stable vitiligo, normal nevocytic nevi and cutaneous melanoma［J］. J Inflamm Res, 2021,14:4111⁃4124. doi: 10.2147/JIR.S321672.
［11］	Kumar Jha A, Sonthalia S, Lallas A, et al. Dermoscopy in vitiligo: diagnosis and beyond［J］. Int J Dermatol, 2018,57（1）:50⁃54. doi: 10.1111/ijd.13795.
［12］	Gupta P, Vinay K, Bishnoi A, et al. A prospective observational study to sequentially determine the dermoscopic features of vitiligo and its association with disease activity in patients on medical treatment: dermoscopy and disease activity in vitiligo［J］. Pigment Cell Melanoma Res, 2023,36（1）:33⁃41. doi: 10. 1111/pcmr.13069.
［13］	胡文婷, 许爱娥. 晕痣的研究进展［J］. 中国皮肤性病学杂志,2017,31（7）:800⁃802. doi: 10.13735/j.cjdv.1001⁃7089.201607001.
［14］	金城, 陆洪光, 赵志国, 等. 晕痣的免疫组化特点与自发性消退机制的研究［J］. 中华皮肤科杂志, 2008,41（4）:237⁃240.doi:10.3321/j.issn:0412⁃4030.2008.04.009
［15］	George EV, Kalen JE, Kapil JP, et al. Comparison of the inflammatory infiltrates in tumoral melanosis, regressing nevi, and regressing melanoma［J］. Am J Dermatopathol, 2019,41（7）:480⁃487. doi: 10.1097/DAD.0000000000001346.
［16］	Park HS, Jin SA, Choi YD, et al. Foxp3（+） regulatory T cells are increased in the early stages of halo nevi: clinicopathological features of 30 halo nevi［J］. Dermatology, 2012,225（2）:172⁃178. doi: 10.1159/000342757.
［17］	Kano S, Nakamura M, Nojiri Y, et al. Differences in the immune microenvironment between improved and non⁃improved cases of vitiligo after halo nevus excision［J］. J Dermatol Sci, 2023,109（3）:136⁃142. doi: 10.1016/j.jdermsci.2023.03.004.
［18］	Yang Y, Li S, Zhu G, et al. A similar local immune and oxidative stress phenotype in vitiligo and halo nevus［J］. J Dermatol Sci, 2017,87（1）:50⁃59. doi: 10.1016/j.jdermsci.2017.03.008.
［19］	Lin F, Hu W, Xu W, et al. CXCL9 as a key biomarker of vitiligo activity and prediction of the success of cultured melanocyte transplantation［J］. Sci Rep, 2021,11（1）:18298. doi: 10.1038/s41598⁃021⁃97296⁃2.
［20］	Lorentzen HF. Eruptive halo naevi: a possible indicator of malignant disease in a case series of post⁃adolescent patients［J］. Acta Derm Venereol, 2020,100（15）:adv00228. doi: 10.2340/ 00015555⁃3568.
［21］	Emre S, Süngü N, Hayran Y, et al. Investigation of the PD⁃1/PD⁃L1 expression in the lesional skins of patients with psoriasis［J］. Dermatol Pract Concept, 2023,13（2）:e2023134. doi: 10.5826/ dpc.1302a134.
［22］	Tan CL, Kuchroo JR, Sage PT, et al. PD⁃1 restraint of regulatory T cell suppressive activity is critical for immune tolerance［J］. J Exp Med, 2021,218（1）:e20182232. doi: 10.1084/jem.20182232.
［23］	曹伟, 冯玉婷, 王小媛, 等. 寻常型白癜风与晕痣患者外周血T淋巴细胞亚群及Th1/Th2、Th17/Treg细胞平衡比较［J］. 实用临床医药杂志, 2020,24（12）:84⁃86. doi: 10.7619/jcmp.2020 12024.
［24］	Halliday GM, Patel A, Hunt MJ, et al. Spontaneous regression of human melanoma/nonmelanoma skin cancer: association with infiltrating CD4+ T cells［J］. World J Surg, 1995,19（3）:352⁃358. doi: 10.1007/BF00299157.
［25］	Schiferle EB, Cheon SY, Ham S, et al. Rejection of benign melanocytic nevi by nevus⁃resident CD4（+） T cells［J］. Sci Adv, 2021,7（26）:eabg4498. doi: 10.1126/sciadv.abg4498.
［26］	Fernández⁃Herrera J, Fernández⁃Ruiz E, López⁃Cabrera M, et al. CD69 expression and tumour necrosis factor⁃alpha immunoreactivity in the inflammatory cell infiltrate of halo naevi［J］. Br J Dermatol, 1996,134（3）:388⁃393.
［27］	Farinazzo E, Zelin E, Agozzino M, et al. Regression of nevi, vitiligo⁃like depigmentation and halo phenomenon may indicate response to immunotherapy and targeted therapy in melanoma［J］. Melanoma Res, 2021,31（6）:582⁃585. doi: 10.1097/CMR.000 0000000000776.
［28］	Ding GZ, Zhao WE, Li X, et al. A comparative study of mitochondrial ultrastructure in melanocytes from perilesional vitiligo skin and perilesional halo nevi skin［J］. Arch Dermatol Res, 2015,307（3）:281⁃289. doi: 10.1007/s00403⁃015⁃1544⁃4.
［29］	Beyer AM, Norwood Toro LE, Hughes WE, et al. Autophagy, TERT, and mitochondrial dysfunction in hyperoxia［J］. Am J Physiol Heart Circ Physiol, 2021,321（5）:H985⁃H1003. doi: 10. 1152/ajpheart.00166.2021.
［30］	Varga G, Gattorno M, Foell D, et al. Redox distress and genetic defects conspire in systemic autoinflammatory diseases［J］. Nat Rev Rheumatol, 2015,11（11）:670⁃680. doi: 10.1038/nrrheum. 2015.105.
［31］	Seneschal J, Boniface K, D′Arino A, et al. An update on Vitiligo pathogenesis［J］. Pigment Cell Melanoma Res, 2021,34（2）:236⁃243. doi: 10.1111/pcmr.12949.
［32］	胡文婷, 黄骏, 许爱娥. 不同治疗方法对晕痣疗效的影响因素分析［J］. 中华皮肤科杂志, 2018,51（2）:121⁃125. doi: 10.3760/cma.j.issn.0412⁃4030.2018.02.008.
［33］	Wang K, Wang Z, Huang W. Resolution of vitiligo following excision of halo congenital melanocytic nevus: a rare case report［J］. Dermatol Ther, 2016,29（3）:145⁃147. doi: 10.1111/dth.12326.
［34］	Hu WT, Lin FQ, Xu AE. Treatment of halo naevus with the topical Janus kinase inhibitor tofacitinib 1.5［J］. Clin Exp Dermatol, 2018,43（8）:935⁃937. doi: 10.1111/ced.13672.
［35］	Abdel Aziz RTA, Awad SS, Mohammed SS. Effectiveness and safety of Chinese cups in the treatment of halo nevi［J］. Dermatol Surg, 2021,47（1）:150⁃151. doi: 10.1097/DSS.0000000000002288.

[1]	Bai Lu, Chu Yan, Liu Yuanyuan, Zhu Caiyong. Treatment of chronic hand eczema [J]. Chinese Journal of Dermatology, 2025, 58(5): 477-480.
[2]	The Consensus Development Expert Group on Diagnosis and Treatment of Port-wine Stain in Chinese Children, Pediatric Dermatologist Committee, China Dermatologist Association. Expert consensus on diagnosis and treatment of port-wine stain in children （2025 edition） [J]. Chinese Journal of Dermatology, 2025, 58(5): 396-404.
[3]	Skin Cancer Research Group, Committee on Dermatology, Chinese Association of Integrative Medicine, Melanoma Society of China Anti-Cancer Association, Society of Integrated Rehabilitation of Skin Tumors, China Anti-Cancer Association. Expert consensus on diagnosis and treatment of pigmented nevi （2025 edition） [J]. Chinese Journal of Dermatology, 2025, 58(5): 387-395.
[4]	Li Ziyu, Lu Yan. Paying attention to severe skin diseases after COVID-19 [J]. Chinese Journal of Dermatology, 2025, 58(4): 378-383.
[5]	Xu Qiuyun, Ji Chao. Pyoderma gangrenosum-related systemic complications [J]. Chinese Journal of Dermatology, 2025, 58(4): 369-373.
[6]	Lyu Mingyue, Man Xiaoyong. Application of cell therapy in systemic lupus erythematosus [J]. Chinese Journal of Dermatology, 2025, 58(4): 374-377.
[7]	Wan Yongjun, Yang Haijing, Yan Qiao, Chen Mei, Wang Fengyuan, Su Qianya, Dong Zhengbang, Wang Fei. Clinical and prognostic analysis of nine cases of immune checkpoint inhibitor-related Stevens-Johnson syndrome/toxic epidermal necrolysis [J]. Chinese Journal of Dermatology, 2025, 58(4): 347-351.
[8]	Group on Pediatric Dermatology, China Dermatologist Association, Committee on Psoriasis, Chinese Society of Dermatology. Expert consensus on the diagnosis and treatment of pediatric pustular psoriasis in China （2025 version） [J]. Chinese Journal of Dermatology, 2025, 58(4): 297-306.
[9]	Chen Qitao, Li Yuqian, Shao Guanghui, Zhu Jing, Zhu Qilin, Li Zhongming, Du Xufeng, Fan Weixin. Erosive pustular dermatosis of the scalp [J]. Chinese Journal of Dermatology, 2025, 58(3): 272-275.
[10]	Chinese Association of Rehabilitation Dermatology, Chinese Society of Dermatology, Photomedicine Therapeutic Equipment Group, Committee on Skin Disease and Cosmetic Dermatology, China Association of Medical Equipment. Clinical application of red, blue, and yellow light therapy in dermatology: an expert consensus statement （2025 edition） [J]. Chinese Journal of Dermatology, 2025, 58(3): 209-215.
[11]	Dermatology Professional Committee of Chinese Research Hospital Society, China Dermatologist Association. Guideline on phototherapy for vitiligo （2025 edition） [J]. Chinese Journal of Dermatology, 2025, 58(3): 197-208.
[12]	Luo Shuaihantian, Long Hai, Lu Qianjin. Research advances in systemic lupus erythematosus in 2024 [J]. Chinese Journal of Dermatology, 2025, 0(3): 20240689-e20240689.
[13]	Xu Zhuohong, Hu Yu, Gu Heng. Role of mesenchymal stem cell-derived exosomes in skin diseases [J]. Chinese Journal of Dermatology, 2025, 0(3): 20220881-e20220881.
[14]	Ye Hui, Deng Shilin, Liang Jingyao, Zhang Xibao. Correlations between the control of atopic dermatitis recurrence and tissue-resident memory T cells [J]. Chinese Journal of Dermatology, 2025, 0(3): 20240192-e20240192.
[15]	Li Xiangqian, Zhang Jianzhong, Zhou Cheng. Advances in the clinical research on systemic small-molecule drugs and biologics for the treatment of alopecia areata [J]. Chinese Journal of Dermatology, 2025, 0(3): 20240247-e20240247.

Research progress in halo nevi

PDF

PDF (Mobile)

Knowledge

Abstract

Cite this article

share this article

References ［35］

Related Articles 15

Metrics

Comments

Recommended 10